A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 1816 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Masking Description: Initially double-blind (until original, pivotal studies AMAK [NCT03482011] and AMAJ [NCT03535194] are locked and unblinded), then open-label.
Primary Purpose: Treatment
Official Title: A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Actual Study Start Date: September 3, 2018
Estimated Primary Completion Date: May 16, 2024
Estimated Study Completion Date: May 16, 2024

Arms:
- Experimental: Mirikizumab Dose 1
- Experimental: Mirikizumab Dose 2